Table 1.
Review characteristics (N=531) | Count (%) |
Year of publication | |
2012 | 50 (9) |
2013 | 79 (15) |
2014 | 67 (12.5) |
2015 | 111 (21) |
2016 | 216 (41) |
2017* | 8 (1.5) |
Cochrane reviews | 125 (24) |
Included primary studies (all designs) per review, mean (SD) (range) | 23 (37) (0–463) |
Reviews including randomised controlled trials | 245 (46) |
Health conditions/ populations | |
Common chronic diseases (eg, diabetes, chronic obstructive pulmonary disease, heart failure, chronic kidney failure, asthma, musculoskeletal conditions) |
106 (20) |
Cancer | 21 (4) |
Critically or terminally ill | 16 (3) |
Patients undergoing lifestyle and prevention interventions | 53 (10) |
Patients undergoing surgical interventions (including preoperative care and safety checklists) | 18 (3) |
Mental health conditions | 67 (12) |
Older adults and aged care | 17 (3) |
Non-communicable diseases (eg, viral hepatitis, HIV, tuberculosis) | 17 (3) |
Maternal and child health | 38 (7) |
Outcomes reported | |
Patient outcomes (health status and/or health behaviours, eg, mortality, morbidity and cure rates) | 492 (93) |
Quality of care (eg, adherence to recommended practice) | 62 (12) |
Access and/or use of healthcare services (eg, waiting time to receive care, readmission rates and length of stay in a facility) | 178 (34) |
Resource use (including healthcare resources, non-healthcare resources, eg, transportation costs, patient and caregiver time) | 161 (30) |
Impacts on equity | 30 (6) |
Social outcomes (eg, poverty and unemployment) | 15 (3) |
Healthcare provider outcomes (eg, well-being, fatigue, stress and satisfaction) | 68 (13) |
Adverse effects | 93 (18) |
Reviews incorporating economic evaluation studies | 177 (33) |
*Incomplete.